Takeda Oncology is proud to announce the FDA approval of ALUNBRIGTM (brigatinib), a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
For Immediate Release
November 1, 2016
Contact: Nancy Bauer
Twin Cities Medical Society Foundation
Patrick J. Flynn, M.D. RECEIVES CHARLES BOLLES BOLLES-ROGERS AWARD
Minneapolis, MN – Patrick J. Flynn, M.D., oncologist/hematologist associated with Minnesota Oncology and Hematology, PA, has been selected to receive the Charles Bolles Bolles-Rogers Award by the Twin Cities Medical Society Foundation (TCMSF). Andrew Thomas, TCMSF Board Member will present the award on Wednesday, November 2, 2016, at a meeting of Minnesota Oncology and guests held at Surly Brewing Company.
The Charles Bolles Bolles-Rogers Award is given to a physician who, in the opinion of the members of the TCMSF selection committee, by reason of his/her professional contribution to medical research, achievement or leadership, has become the outstanding physician of this and other years. The award, a bowl, is named after Mr. Charles Bolles Bolles-Rogers, an “aristocratic” gentleman who lived in the Minneapolis area for 37 years and was especially interested in the health and hospital needs of the city. He served on the (former) St. Barnabas Hospital Board of Trustees and was president of that board for many years. Prior to his death he made provision for the Charles Bolles Bolles-Rogers Award to be given annually to an outstanding physician. Dr. Frederick B. Rogers, grandson of the late Mr. Bolles-Rogers and Trauma Program Medical Director, Lancaster General Hospital, Lancaster, PA, will participate in the presentation and offer a few words about his grandfather’s legacy.
Patrick J. Flynn, M.D. is a highly accomplished and dedicated oncologist/hematologist and is widely recognized for his clinical research—particularly serving for 30 years as the principal investigator for the National Cancer Institute Grant Funded Metro Minnesota Clinical Community Oncology Project (CCOP). It was his vision to bring together, often fiercely competitive, cancer care providers and institutions throughout the Twin Cities, for the greater good—bringing innovative research to cancer patients in our community where thousands of patients were enrolled in cancer investigation trials.
Dr. Flynn has been described as an excellent and compassionate physician, an outstanding teacher and a leader in cutting edge research. His colleagues agree. In March 2013, Dr. Flynn received the Association of Community Cancer Centers’ David King Community Clinical Scientist Award, which recognizes the top clinical oncologists throughout the country.
As a leader, Dr. Flynn co-founded and served as the Medical Director of the Autologous Bone Marrow and Stem Cell Transplant program at Abbott Northwestern Hospital and served as Director of the Virginia Piper Cancer Institute.
And, as an educator he is a Clinical Professor at the University of Minnesota providing medical education to residents at Abbott Northwestern hospital; is a highly sought-after speaker—locally and nationally; co-chairs the annual hematology oncology review course and is well-published with nearly 100 peer-reviewed publications.
Dr. Flynn truly embodies the criteria of the Charles Bolles Bolles-Rogers award as a researcher, leader, teacher and an outstanding physician. The Twin Cities Medical Society Foundation is honored to award Dr. Patrick J. Flynn, the Charles Bolles Bolles-Rogers Award.
November 1, 2016
A special thank you goes out to our expert speaker Dr. Linda Hawes Clever, our board members, and our fellows for their participation and contribution to a successful Fellows Career Orientation Workshop.
July 25, 2016
On June 29, 2016, the Minnesota Cancer Moonshot Summit will open the dialogue to generate ideas and commitments to accelerate the pace of progress in cancer research, prevention, treatment, and survivorship. Individuals and organizations representing the entire cancer community and beyond will convene under the national charge to double the rate of progress toward a cure.
Click here for more information about this event.
June 20, 2016
The Association of Community Cancer Centers (ACCC) has selected Park Nicollet HealthPartners, Frauenshuh Cancer Center, as one of its 2016 Innovator Award winners. In its sixth year, this prestigious honor is awarded to Cancer Program Members that develop innovative solutions for the effective delivery of cancer care.
Opioids remain a mainstay for oncology pain management but long-term use poses numerous challenges. Frauenshuh Cancer Center led an 18-month initiative to improve patient understanding of opioid use, educate clinicians on opioid costs and comparative effectiveness, and implement a nursing protocol to document personal pain goals (PPG). Learn how this pain intervention improved rates of PPG documentation, streamlined work processes, decreased out-of-pocket costs, and enhanced both patient and provider experience.
Since 2011, the ACCC Innovator Awards have honored exceptional cancer programs that advance the goal of improving cancer care access, quality and value. Hear inspiring presentations from the 2016 Innovator Award recipients at the ACCC 33rd National Oncology Conference, October 19-21, 2016, in St. Louis, Missouri. Save $100 with early bird registration rates through August 15.
May 3, 2016
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment with platinum-based chemotherapy.
The U.S. approval follows the recent marketing authorization of Gilotrif in this patientpopulation by the European Commission. Gilotrif, an oral, once-daily EGFR-directed therapy, is currently approved in the U.S. for the first-line treatment of specific types of EGFR mutation-positive NSCLC.
Read the corporate press release here.
April 29, 2016
On March 4, 2016, the U.S. Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).
Learn more here.
April 1, 2016
Cancer in Tanzania, Hope for Women & Children is a one-day symposium occurring Saturday, April 16, 2016. Hosted by the Foundation for Cancer Care in Tanzania, this symposium will focus on those malignancies having the greatest impact on children and their mothers, the challenges which exist in prevention, early detection and providing treatment, along with the opportunities for improved outcomes.
For more information, including the complete agenda and registration, please click here.
March 11, 2016
Last week, MSCO joined with the Association of Community Cancer Centers (ACCC), American Society of Clinical Oncology (ASCO), the Community Oncology Alliance (COA), and approximately 100 other organizations in a letter to HHS Secretary Sylvia Burwell and Acting CMS Administrator Andy Slavitt expressing “strong concern” about the agency’s plans to put forward a proposed rule for the Medicare Part B Drug Payment Model and asking the agency not to proceed with the initiative.
The rule is scheduled to be published in the March 11 Federal Register. Comments on the proposed rule are due by May 9.
March 9, 2016
The U.S. Food and Drug Administration (FDA) on Sept. 22, 2015, approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other treatments.
October 8, 2015
To raise awareness and advance cancer treatment and science, the American Cancer Society and Genentech have teamed up to provide About Clinical Trials (ACT).
ACT is a series of unbiased videos and patient resources. Study participants, clinicians, thought leaders, nurses, and others share their experience in order to educate and inspire patients, caregivers, and physicians to act by considering enrollment in cancer clinical trials. Society Chief Medical Officer Otis W. Brawley, MD, is featured.
Go to LearnAboutClincialTrials.org to learn more about clinical trials and access resources to help patients make educated decisions about their treatment, including the American Cancer Society's Clinical Trials Matching Service. Constituents may also call the American Cancer Society National Call Information Center (NCIC) at 800.227.2345 to receive a free patient kit, which contains an educational brochure with a DVD and USB drive, and also directs inquiries to the Clinical Trials Matching Service.
August 25, 2015
August 27 at Noon, EST, join Niesha Griffith, RPh, MS, FASHP, Administrator of Oncology Pharmacy and Infusion Services at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University and Bill McGivney, PhD, Principal of McGivney Global Advisers for a complimentary webinar to discuss the intricate coverage and reimbursement issues related to immuno-oncology agents. Brought to you by the Institute for Clinical Immuno-Oncology (ICLIO) An Institute of ACCC.
Discussion will include:
-Determination of coverage and reimbursement for I-O agents
-Present coverage for I-O agents
-Impact of new Oncology Value Metrics
-Institutional considerations and needs
-Assurance of explicit, timely, and clear coverage policies
-Reimbursement issues in contracting, pilot projects etc.
Click here to register.
August 14, 2015
ACCC members are invited to join Dr. Michael Postow for an interactive webinar on the role of immunotherapy in treating patients with advanced melanoma. As part of the Principles and Application of Immunotherapy of Cancer series, this free, CME/ANCC/APCE-certified webinar will be held this Friday, May 22, from 7:30 am - 8:30 am ET.
Your cancer program can host a private webinar on integrating immunotherapy into the treatment of melanoma or lung cancer, at no charge. Email Lorna Lucas or call 866.690.9902 for more information.
May 20, 2015
This two-day symposium will explore the need for cancer care in Tanzania, the challenges involved in delivering care, and the opportunities for moving forward.
The intended audience of this two-day symposium hosted by the Foundation for Cancer Care in Tanzania is physicians, APPs, pharmacists, radiation technical professionals, health administrators, and anyone with an interest in global health.
For more information, including the complete agenda and registration, please click here.
April 21, 2015
The Association of Community Cancer Centers (ACCC), on behalf of MSCO, has joined HHS' Health Care Payment Learning and Action Network, a collaborative network of payers, employers, providers, patients, states, and consumer groups, who will work together to generate knowledge, capture best practices, disseminate information, and apply lessons learned that support the increased adoption of value-based payments in Medicare.
The network was created in tandem with HHS Secretary Burwell's January announcement that set tangible goals to shift Medicare payments towards value-based payments.
April 3, 2015
On Feb. 18, 2015, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for Revlimid (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma.
Read company press release here.
March 3, 2015
Principles and Application in Immunotherapy of Cancer is a CME/ANCC/ACPE certified education series designed for multidisciplinary oncology care teams. Presented in an interactive webinar format, the series will provide a full overview of the core principles of immunotherapy and a review of issues related to the clinical application of these therapies in Melanoma and Lung Cancer from the convenience of your own office. Cancer practices can choose to participate in one or both of these 60-minute tumor-specific tracks. The series has been developed by a faculty committee composed of 1 physician expert and 1 nurse practitioner along with input from 10 additional presenting faculty.
This private webcast provides your practice with exclusive access. The format is designed so that your team members can learn and connect directly with expert faculty well versed in immunotherapy principles and clinical application. The opportunity is available at no cost to participating practices.
This series is jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC, in partnership with ACCC.
If your cancer practice is interested in participating, or if you would like more information, please contact me at directly at email@example.com.
February 3, 2015